Three systems of immunoradiometric assays (IRMAs), a two-site monoclonal antibody sandwich IRMA (MAb-IRMA), two-site polyclonal antibody-monoclonal antibody sandwich IRMA (PAb-MAb-IRMA), and two-site polyclonal antibody sandwich IRMA (PAb-IRMA), were developed to detect low-grade infections with Plasmodium falciparum. The assays showed good correlation with parasitemia when tested against parasites from in vitro cultures (r = 0.996, 0.994, and 0.998 for MAb-, PAb-MAb-, and PAb-IRMA, respectively), with the ability to detect as few as 0.24, 0.67, and 1.82 parasites per 107 erythrocytes, respectively. The assays were specific for P. falciparum, since a serially diluted specimen from a patient with vivax malaria with an initial parasitemia of 0.8% and almost al of the undiluted specimens from five other vivax malaria patients were negative. The assays were performed on patients with falciparum malaria before and after treatment with antimalarial drugs. Before treatment, all 24 patients were positive by all three systems of two-site sandwich IRMAs. Two weeks after treatment, 81.8% (18 of 22) of the patients were positive by microscopic examination, but the IRMA positivity rates were 90.9% (20 of 22), 86.4% (19 of 22), and 81.8% (18 of 22) for MAb-, PAb-MAb-, and PAb-IRMA, respectively. Four weeks after treatment, all 19 patients were negative by microscopic examination, but 52.6% (10 of 19) of the patients were still positive with MAb-and PAb-MAb-IRMA and 31.6% (6 of 19) were positive with PAb-IRMA. Comparison between the three systems of IRMA showed that the MAb-IRMA was superior to the other two systems for three reasons. First, it gave a lower count when tested with blood from healthy individuals. Second, it gave a higher count when tested with blood from patients with falciparum malaria. Third, it gave better correlation with parasitemia when blood from falciparum malaria patients was tested. MAb-IRMA is recommended for use for the detection of low-grade P. falkiparum infection.
Demonstration of antigens is becoming increasingly popular in the diagnosis of parasitic diseases because they are more closely related to present illness than are antibodies which can be detected even when the etiologic agent has disappeared. Diagnostic tests based on antigen detection have been developed for several parasitic diseases, including amebiasis (9, 15) , giardiasis (8, 16) , toxoplasmosis (1) , and schistosomiasis (6) . Detection of sporozoites of Plasmodium falciparum and Plasmodium vivax in infected mosquitoes has been done successfully by immunoradiometric assay (IRMA) or enzyme-linked immunosorbent assay (4, 5, 20, 21) . The presence of blood-stage antigen in P. falciparuminfected erythrocytes has been demonstrated with a competitive binding radioimmunoassay (RIA) using polyclonal antibodies (PAb) with a sensitivity of detecting one to eight parasites per 106 erythrocytes (2, 11, 12) .
We have recently developed a competitive binding RIA with anti-P. falciparum immunoglobulin G (IgG) prepared from people living in an area where malaria is endemic in Thailand and IgG from a monoclonal antibody (MAb) against blood stages of P. falciparum prepared in our laboratory, with sensitivities of detecting 13 and 2.2 parasites per 106 erythrocytes, respectively (10) . We also showed that our MAb bound to the parasite antigen more specifically than did the polyclonal IgG (PIgG). The competitive-binding RIA appears to be less sensitive than microscopic examination by * Corresponding author.
an experienced microscopist, who could detect as few as one parasite per 5 x 106 erythrocytes (14) . The objectives of the present study were to develop a two-site sandwich IRMA, which is considered a more sensitive method for detection of antigen than the competitive-binding RIA, using MAb and PAb and to select the assay system for future use by comparing the results with MAb, PAb, and a combination of the two. Control antigen. Normal erythrocytes from healthy individuals were washed three times in PBS by centrifugation at 500 x g for 10 min at room temperature, and the plasma as well as the buffy coat layer was removed. The washed cells were lysed in 9 volumes of BBS-NP40 at room temperature, followed by centrifugation at 9,980 x g for 10 min at room temperature to remove nuclei and cell debris. The supernatant was then used as the control antigen and as the diluent for the standard parasite antigen (11) .
MATERIALS AND METHODS

Subjects. (i) Patients
Preparation of anti-P. falciparum antibody. (i) PAb. A rabbit was initially immunized subcutaneously at multiple sites with 1 ml of a suspension of 107 parasites of the SO strain of P. falciparuft, of which most were in the late trophozoite and schizont stages, in physiological saline (0.85% NaCI solution) incorporated in an equal volume of Freund complete adjuvant. This was followed by three other monthly injections of 1 x 107, 4 x 107, and 4 x 107 parasites, respectively, in Freund incomplete adjuvant. The animal was bled by cardiac puncture 3 weeks after the last injection. The serum was inactivated by heating at 56°C for 30 min and was absorbed by mixing 1 ml of the serum with 4 ml of packed group AB erythrocytes from healthy individuals, incubated at 37°C for 30 min and at 4°C overnight, followed by centrifugation at 500 x g for 10 min at room temperature, and the supernatant was kept at -70°C until used.
(il) MAb. The F2W22C1 MAb prepared from the culture supernatant was used. This MAb was produced by fusion of Sp2/0 myeloma cells with spleen cells from a BALB/c mouse immunized with the SO strain of P. falciparum as described previously (10) . It reacted in the indirect fluorescentantibody test with the ring as well as all other stages of P. falciparum in 27 of 31 isolates tested (10) .
Radioiodination of anti-P. falkiparum IgG. IgG fractions from either PAb or MAb against P. falciparum were prepared by protein A-Sepharose 4B (Pharmacia) chromatography by the technique provided by the manufacturer. Two hundred micrograms of IgG, determined by a spectrophotometric method (19) , was labeled with 2 mCi of carrier-free 125I (Amersham, England) by the iodogen tube method (13) . The percent incorporation and specific activity were 97.69% and 4.2 x 106 cpm/,ug of protein, respectively, for labeled PIgG and 95.44% and 9.6 x 106 of cpm/,ug of protein, respectively, for monoclonal IgG (MIgG). The labeled IgG was kept in small portions in PBS (pH 7.2) containing 1% bovine serum albumin (BSA) fraction V (RIA grade; US Biochemical Corp.) at -70°C and thawed only once, just before use. The labeled IgG solution was centrifuged at 9,980 x g for 10 min at room temperature to remove any formed aggregates, further diluted with BBS containing 0.5% BSA, and used at a concentration of 0.1 and 0.4 ,ug of protein per 30 pI for MIgG and PIgG, respectively.
IRMA. Wells of 96-well U-bottom assay plates (Falcon 3911 Microtest III; Becton Dickinson and Co., Paramus, N.J.) were each coated with 50 ,ul of MIgG or PIgG in 0.05 M sodium bicarbonate buffer, pH 9.6, at a concentration of 10 ,ug/ml, followed by incubation at 37°C for 3 h or at 4°C overnight. The plates were washed three times with BBS-0.5% BSA, saturated with 100 ,ul of BBS containing 1% BSA (BBS-1% BSA), and kept for 1 h at room temperature and at 4°C thereafter until used. The plates were thoroughly washed with BBS-0.5% BSA to which 30 pil of either the erythrocyte preparations to be tested or standard antigen in various dilutions was added to each well, followed by incubation for 3 h at room temperature. The plates were washed twice with BBS-0.5% BSA containing 0. in PBS-1% BSA and 10% normal human serum were added, and the plates were incubated for another 3 h at room temperature. After being washed three times with BBS, the wells were cut out and placed directly into counting tubes, and bound radioactivity was measured in a ganima counter (Mini-Assay type 6-20; Mini Instruments Ltd., London, England). Three systems of IRMA were developed: (i) a two-site MAb sandwich IRMA (MAb-IRMA), in which the plates were coated with unlabeled MIgG and detected with labeled MIgG; (ii) a two-site PAb-MAb sandwich IRMA (PAb-MAb-IRMA), in which the plates were coated with unlabeled PIgG and detected with labeled MIgG; and (iii) a two-site PAb sandwich IRMA (PAb-IRMA), in which the plates were coated with unlabeled PIgG and detected with labeled PIgG. All assays were done in duplicate, with an intrarun difference of less than 5%, and the means (± standard deviation [SDI) of the coefficient of variation for 12 samples in four different runs were 10. 
RESULTS
Sensitivity and specificity of IRMA. The assay performed on blood samples from 30 healthy individuals showed that the mean In cpm (MLC) (± SD) was 6.2032 ± 0.194, 6.6113 ± 0.133, and 7.209 ± 0.130 cpm for MAb-, PAb-MAb-, and PAb-IRMA, respectively. A sample was considered positive if its binding was above the MLC + 4 SD of 6.9792 for the MAb-IRMA, 7.1433 for the PAb-MAb-IRMA, and 7.729 for the PAb-IRMA (equivalent to 1,074, 1,265, and 2,273 cpm, respectively).
The cutoff levels in the above three systems were used to determine the sensitivity of IRMA when various dilutions of P. falciparum-infected erythrocytes from in vitro cultures were allowed to react with antiplasmodial antibodies. The sensitivity of the IRMA was 0.24, 0.67, and 1.82 parasites per 107 erythrocytes with MAb-, PAb-MAb-, and PAb-IRMA, respectively (Fig. 1) .
The specificity of the assay was determined in a serially diluted suspension of P. vivax-infected erythrocytes from one patient with vivax malaria with an initial parasitemia of 0.8% (Fig. 1 ) and in undiluted blood samples from five other vivax malaria patients, one of whom was asymptomatic (Table 1) . Binding was below the cutoff level for each system in all cases except one (patient 3) , in which the PAb-MAb-IRMA binding activity (7.2269 In cpm) was a little above the cutoff MLC level of 7.1433 In cpm).
Application of IRMA to clinical specimens. The blood from malaria patients collected before treatment and at various times thereafter was tested in duplicate only once with all three systems of IRMA, and the results were compared with 0.886, Fig. 3 ). With the two other assay systems (data not shown), similar findings were observed, but with a lower degree of correlation (r = 0.803 and 0.638 for PAb-MAb-and PAb-IRMA, respectively).
DISCUSSION
Detection of low-grade parasitemia has recently been a subject of intense investigation by RIA, enzyme immunoassay, and DNA probes (2, 3, 7, 11, 12 Comparison between the three assay systems used in this study showed that the MAb-IRMA was superior to the other two assay systems for three reasons. First, it gave the lowest MLC (6.20) when tested with erythrocytes from healthy individuals, whereas those assayed with the PAb-MAb-and PAb-IRMA showed a higher MLC (6.61 and 7.20, respectively). Second, it correlated more closely with parasitemia in clinical specimens (r = 0.886) than the PAb-MAb-and PAb-IRMA (r = 0.803 and 0.638, respectively). Third, it gave higher radioactive counts with P. falciparum-positive specimens than the other two systems. It is therefore recommended that the MAb-IRMA be used in future trials with clinical specimens and in the field.
The nature of the antigen detected with our assay systems has not been determined. Neither do we know whether the antigen detected is associated with living or dead parasites or soluble parasite products. The high IRMA-positive rates for patients 4 weeks after treatment, when parasites were no longer detected by microscopic examination, suggested that the parasite molecules reacting with our MAb or PAb were present even when they were degenerated and thus could not be recognized even by experienced microscopists. Our IRMA is therefore inferior to parasitological examination in the assessment of therapeutic cure, but it is more practical than parasitological examination in a large-scale survey of specimens collected from the field, especially when parasitemia is low.
The MAb-IRMA developed in our laboratory could have wide applications, including field monitoring of the malaria control program, assessing the effectiveness of field trials of a future malaria blood-stage vaccine, detecting early recrudescence of malaria after chemotherapy, and screening blood donors. The radioisotope technique used in this study may, at present, preclude the assays from field use, but it could be substituted for the enzymatic techniques, which we are planning to develop in the near future.
